Special Drug Use-results Surveillance of Scemblix Tablets

Novartis

Status: Completed

Conditions: Chronic Myeloid Leukemia

Treatments: Other: Asciminib

Study type: Observational

Funder types: Industry

Identifiers

NCT05421091

CABL001A1401

Details and patient eligibility

About

Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.

Full description

The objective of this study is to collect data on the occurrence, severity, clinical courses of the safety specifications of asciminib, identify factors etc. involved in occurrence and assess its clinical safety inresistant/intolerant chronic myelogenous leukemia patients during an observational period of 48 weeks from the start of treatment with asciminib.

Enrollment: 550 patients

Sex: All

Ages: Under 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients treated with asciminib in Japan.

Exclusion criteria

NA

Trial design

550 participants in 1 patient group

Asciminib

Description:

Patients prescribed with Asciminib

Treatment:

Other: Asciminib